ZOLL Medical has completed its previously announced acquisition of medical device and digital health company Itamar Medical.

The acquisition closed nearly three months after ZOLL signed a definitive agreement to acquire Itamar Medical for nearly $538m.

As agreed, Itamar Medical will now operate as a business division within ZOLL. The former CEO of Itamar Medical, Gilad Glick, will lead the business.

The acquired firm’s main operations in Caesarea, Israel, are also expected to continue with no material impact.

Itamar Medical focuses on developing non-invasive medical devices and solutions to help diagnose respiratory sleep disorders. The company’s main product, the WatchPAT Home Sleep Apnea Device, is available in the US, Europe and Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The acquisition will enable ZOLL to enhance its offerings for undiagnosed and untreated cardiac patients.

ZOLL CEO Jon Rennert said: “We are pleased to announce the closing of the acquisition of Itamar and welcome its employees to the ZOLL family.

“Together, ZOLL and Itamar Medical will help more patients receive diagnosis and treatment for sleep-disordered breathing and help strengthen the collaboration between the worlds of cardiology and sleep medicine.”

An Asahi Kasei subsidiary, ZOLL delivers medical devices and software solutions for emergency care as well as to boost clinical and operational efficiencies.

Last year, ZOLL secured US Food and Drug Administration (FDA) approval for its TherOx System.

The TherOx System is designed to provide SuperSaturated Oxygen (SSO₂) Therapy and reduce heart muscle damage in ‘widowmaker’ heart attack patients.